Developer of an immune system technology designed to provide treatments for oncology and auto-immune disorders.
Developer of an immune system technology designed to provide treatments for oncology and auto-immune disorders.
Discovery Tools (Healthcare)📍 New York, NYFounded 2018
Current Valuation
$960M
as of 2021-Q4
PRIVATE
QL Price
$674.21M
-30% vs last round
QuantLogix's current estimate for Immunai, published 2026-09-27 — below the last disclosed round of $960M (2021-Q4).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$960M
2021-Q4
weight 0.04
Secondary market print
$655.68M
2026-06-27
weight 0.58
How this price has held up
No round has priced for Immunai since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Immunai, 2026-09-27 (90dbdc14dbf8de3e).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Immunai going public?
No. Immunai is private and has not filed to go public. There is no S-1 on file.
What is Immunai's valuation in 2026?
Immunai is valued at $960M as of 2021-Q4, set by its Series C ($204M, Dec 2021). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Immunai filed an S-1?
No public S-1 is on file for Immunai.
How much has Immunai raised?
Immunai has raised $583.52M in total, most recently a Series C of $204M in Dec 2021.
Is Immunai publicly traded — can you buy Immunai stock?
No. Immunai is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Immunai on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2018
HQ
New York, NY
Employees
180
Total Raised
$583.52M
Last Round
Series C — $204M (Dec 2021)
IPO Status
private
Fundraising Status
Series C · $204M · 4y 9mo ago
privateTotal raised $583.52M
Secondary Market
Implied price / share
$127.25
Last round price / share
$186.34
vs last round
-31.7%
Open interest
1
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series C
$204M
Dec 2021
—
$960M
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Immunai — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-19. Re-checked weekly.
Talent Signal
Hiring trend
▲ Hiring uptrend
+20% vs 2026-08
Open roles
18
via careers page
Product-build share
72%
engineering, research, product, design
Trajectory
expanding
heavy product build — 72% of open roles are product-building functions (engineering/research/product) — 6 of 18 open roles are engineering.
No tracked executive churn; open roles trending up.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Software Engineering (4)AI Researcher – Agentic AIClinical Project ManagerComputational Biologist II, External CollaborationsData Infrastructure Team LeadSoftware Engineering
Counted from Immunai's live job board as of 2026-09-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2021-Q4. Refreshed quarterly.